NCT00736047

Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

A Double Blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.

Conditions

• Smokers

Interventions

Type	Name	Description
BIOLOGICAL	NIC002
BIOLOGICAL	Placebo

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2008-08-15
• Last updated: 2017-03-21

Locations

2 sites across 1 country: Germany